Linagliptin Krka

Linagliptin, the active ingredient in Linagliptin Krka, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It is used to improve glycaemic control in adults with type 2 diabetes mellitus. GNH USA supplies Linagliptin Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by insulin resistance and impaired insulin secretion.

Type 2 diabetes mellitus: improves glycaemic control by enhancing glucose‑dependent insulin secretion and reducing hepatic glucose production.

Linagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nasopharyngitis: mild upper‑respiratory tract infection. - Headache: transient mild to moderate pain. - Dizziness: occasional light‑headedness. - Gastrointestinal upset: nausea, abdominal discomfort. - Upper respiratory infection: cough, sore throat. - Back pain: musculoskeletal discomfort.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring medical attention. - Severe allergic reactions: rash, angioedema, anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice. - Hypoglycaemia (when combined with insulin or sulfonylureas): dizziness, sweating, confusion. - Bullous pemphigoid: blistering skin disorder. - Stevens‑Johnson syndrome: severe mucocutaneous reaction.

When prescribing Linagliptin, clinicians should consider several safety aspects.

Renal impairment: monitor renal function and adjust therapy as needed. Hepatic impairment: use with caution in patients with liver disease. Cardiovascular disease: observe for any worsening of cardiac status. Elderly patients: start at the recommended dose and monitor for adverse effects. Pregnancy and lactation: safety not established; avoid unless clearly needed. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Linagliptin may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure. - Insulin or sulfonylureas: heightened risk of hypoglycaemia. - Rifampin: may lower linagliptin plasma concentrations.

Moderate Interactions (Monitor Closely):\n- Diuretics: watch for electrolyte disturbances. - ACE inhibitors: monitor blood pressure for additive hypotensive effect. - Warfarin: assess INR regularly for potential interaction.